Journey Medical Corporation Amends Credit Agreement, Extends $25 Million Term Loan Maturity to June 2028
**Journey Medical Corporation Extends and Amends $25 Million Loan Facility** Journey Medical Corporation has announced it entered into a Third Amendment to its existing credit agreement with SWK Funding LLC and other financial institutions on September 25, 2025. The amendment extends the maturity date of its $25 million term loan from December 27, 2027, to June 27, 2028. The revised agreement also adjusts the principal repayment schedule: starting February 2026, Journey Medical must make quarterly repayments equal to 7.5% of the funded loan principal. However, if the company surpasses $60 million in trailing twelve-month revenue by December 31, 2025, repayments are deferred until February 2027, increasing to 10% of the principal per quarter. The amendment aims to provide Journey Medical with greater financial flexibility as it continues its operations and growth initiatives.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-093891), on September 26, 2025, and is solely responsible for the information contained therein.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。